Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

(2022) Domenica M. Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

(2022) John P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

(2022) Leigh Perreault et al.   DIABETES CARE

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

(2021) Sean Wharton et al.   INTERNATIONAL JOURNAL OF OBESITY

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

(2020) Robert F. Kushner et al.   Obesity

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

(2017) Carel W le Roux et al.   LANCET

Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation

(2017) G.A. Bray et al.   Obesity Reviews

2. Classification and Diagnosis of Diabetes

(2016)   DIABETES CARE

Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?

(2015) Donald A. Williamson et al.   Obesity

NIH working group report: Innovative research to improve maintenance of weight loss

(2014) Paul S. MacLean et al.   Obesity

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   CIRCULATION

Notice

(2012)   Kidney International Supplements

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Four-Year Weight Losses in the Look AHEAD Study: Factors Associated With Long-Term Success

(2011) Thomas A. Wadden et al.   Obesity

C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization

(2010) N J Timpson et al.   INTERNATIONAL JOURNAL OF OBESITY

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Strategies for Sustaining Weight LossThe Weight Loss Maintenance Randomized Controlled Trial

(2008) Laura P. Svetkey   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION